Skip to main content
. 2022 Sep 27;12:969569. doi: 10.3389/fonc.2022.969569

Figure 2.

Figure 2

Progression-free survival with nivolumab plus ipilimumab according to the densities of certain T cell subsets, CD20+ B cells, and M1 macrophages at the tumor margin. (A) Foxp3- CD4+ helper T cells, (B) CD68+ CD206- M1 macrophages, (C) CD137+ CD8+ cytotoxic T cells, (D) CD137+ CD4+ T cells, (E) CD20+ B cells.